The study’s result revealed more consistent data than the studies performed on monoclonal agents against IL-5, which noted mixed results on COPD exacerbations and no effect on lung function, symptom relief, or improvement in quality of life. The gene discussed is IL5; the disease is chronic obstructive pulmonary disease.